19 June 2013
Keywords: roche, gi, cancer, therapy, good, folfox, swiss
Article | 26 January 2009
Swiss drug major Roche presented overall survival results from a 14-month follow-up of the Phase III NO16966 study confirming that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 January 2009
18 June 2013
© 2013 thepharmaletter.com